A regulatory perspective on recombinant collagen-based medical devices

Abstract

As a class of novel biomaterials manufactured by synthetic biology technologies, recombinant collagens are candidates for a variety of medical applications. In this article, a regulatory scientific perspective on recombinant collagens and their medical devices is presented with a focus on the definition, translation, classification and technical review. Recombinant collagens are categorized as recombinant human collagen, recombinant humanized collagen and recombinant collagen-like protein, as differentiated by specific compositions and structures. Based on their intended uses and associated risks, recombinant collagen-based medical devices are generally classified as Class Ⅱ or Ⅲ in China. The regulatory review of recombinant collagen-based medical devices aims to assess their safety and efficacy demonstrated by scientific evidences generated from preclinical and clinical evaluations. Taken together, opportunities as well as challenges for their future clinical translation of recombinant collagen-based medical devices abound, which highlights the essential role of regulatory science to provide new tools, standards, guidelines and methods to evaluate the safety and efficacy of medical products.

Graphical abstract

Highlights

• •

  Recombinant collagens are novel biomaterials manufactured by biosynthesis methods.

• •

  The first regulatory article on recombinant collagen-based medical devices.

• •

  Recombinant collagen-based medical devices are defined and classified by NMPA.

• •

  Regulatory review assesses the safety and efficacy of medical devices.

• •

  Translation of recombinant collagens from bench to clinic needs regulatory science.